NIH To Begin Ebola Vaccine Safety Clinical Trial In Humans
News outlets report on an Ebola vaccine human clinical trial scheduled to begin next week.
ABC News: U.S. to Test Ebola Vaccine in Humans Amid Growing Outbreak in West Africa
“U.S. scientists will begin testing an Ebola vaccine in humans next week, health officials announced [Thursday]. But it could take 11 months to learn whether the vaccine is safe as the virus’ toll in West Africa continues to rise…” (Moisse, 8/28).
Associated Press: U.S. to begin safety testing Ebola vaccine next week
“The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency’s National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Beginning Tuesday, it will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems…” (Borenstein, 8/28).
Politico: NIH Ebola vaccine trial to start next month
“…With the National Institute of Allergy and Infectious Diseases taking the lead in this multinational effort, the study will first enroll three healthy volunteers at the NIH campus in Maryland and then expand to 20 volunteers between the ages of 18 and 50. Later in September, 60 volunteers will be enrolled at the Oxford University in England and 120 volunteers in The Gambia and Mali…” (Villacorta, 8/28).
Washington Post: Ebola vaccine to be tested in humans at NIH Clinical Center in Maryland this fall
“…The vaccine is designed to deliver one part of Ebola’s genetic material to human cells, eventually triggering an immune response in the patient. The vaccine, however, does not allow Ebola genes to replicate…” (Dennis, 8/28).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.